Role and Clinical Importance of Progressive Changes in Echocardiographic Parameters in Predicting Outcomes in Patients With Hypertrophic Cardiomyopathy
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
BACKGROUND: The prognostic utility of follow-up transthoracic echocardiography (FU-TTE) in patients with hypertrophic cardiomyopathy (HCM) is unclear, specifically in terms of whether changes in echocardiographic parameters in routine FU-TTE parameters are associated with cardiovascular outcomes. METHODS: From 2010 to 2017, 162 patients with HCM were retrospectively enrolled in this study. Using echocardiography, HCM was diagnosed based on morphological criteria. Patients with other diseases that cause cardiac hypertrophy were excluded. TTE parameters at baseline and FU were analyzed. FU-TTE was designated as the last recorded value in patients who did not develop any cardiovascular event or the latest exam before event development. Clinical outcomes were acute heart failure, cardiac death, arrhythmia, ischemic stroke, and cardiogenic syncope. RESULTS: Median interval between the baseline TTE and FU-TTE was 3.3 years. Median clinical FU duration was 4.7 years. Septal trans-mitral velocity/mitral annular tissue Doppler velocity (E/e’), tricuspid regurgitation velocity, left ventricular ejection fraction (LVEF), and left atrial volume index (LAVI) at baseline were recorded. LVEF, LAVI, and E/e’ values were associated with poor outcomes. However, no delta values predicted HCM-related cardiovascular outcomes. Logistic regression models incorporating changes in TTE parameters had no significant findings. Baseline LAVI was the best predictor of a poor prognosis. In survival analysis, an already enlarged or increased size LAVI was associated with poorer clinical outcomes. CONCLUSIONS: Changes in echocardiographic parameters extracted from TTE did not assist in predicting clinical outcomes. Cross-sectionally evaluated TTE parameters were superior to changes in TTE parameters between baseline and FU at predicting cardiovascular events.
Abstract
BACKGROUND: The prognostic utility of follow-up transthoracic echocardiography (FU-TTE) in patients with hypertrophic cardiomyopathy (HCM) is unclear, specifically in terms of whether changes in echocardiographic parameters in routine FU-TTE parameters are associated with cardiovascular outcomes. METHODS: From 2010 to 2017, 162 patients with HCM were retrospectively enrolled in this study. Using echocardiography, HCM was diagnosed based on morphological criteria. Patients with other diseases that cause cardiac hypertrophy were excluded. TTE parameters at baseline and FU were analyzed. FU-TTE was designated as the last recorded value in patients who did not develop any cardiovascular event or the latest exam before event development. Clinical outcomes were acute heart failure, cardiac death, arrhythmia, ischemic stroke, and cardiogenic syncope. RESULTS: Median interval between the baseline TTE and FU-TTE was 3.3 years. Median clinical FU duration was 4.7 years. Septal trans-mitral velocity/mitral annular tissue Doppler velocity (E/e’), tricuspid regurgitation velocity, left ventricular ejection fraction (LVEF), and left atrial volume index (LAVI) at baseline were recorded. LVEF, LAVI, and E/e’ values were associated with poor outcomes. However, no delta values predicted HCM-related cardiovascular outcomes. Logistic regression models incorporating changes in TTE parameters had no significant findings. Baseline LAVI was the best predictor of a poor prognosis. In survival analysis, an already enlarged or increased size LAVI was associated with poorer clinical outcomes. CONCLUSIONS: Changes in echocardiographic parameters extracted from TTE did not assist in predicting clinical outcomes. Cross-sectionally evaluated TTE parameters were superior to changes in TTE parameters between baseline and FU at predicting cardiovascular events.
참고문헌 (28)
- Maron BJ, "Hypertrophic cardiomyopathy : a systematic review", JAMA, 287, pp.1308~1320 (2002)
- Task Force members, "2014ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy", Eur Heart J, 35, pp.2733~2779 (2014)
- Klues HG, "Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy : morphologic observations and significance as assessed by twodimensional echocardiography in 600 patients", J Am Coll Cardiol, 26, pp.1699~1708 (1995)
- Elliott PM, "Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy", Lancet, 357, pp.420~424 (2001)
- Finocchiaro G, "How does morphology impact on diastolic function in hypertrophic cardiomyopathy? A single centre experience", BMJ Open, 4, pp.e004814~ (2014)
- Maron BJ, "Implications of left ventricular remodeling in hypertrophic cardiomyopathy", Am J Cardiol, 81, pp.1339~1344 (1998)
- Biagini E, "Dilated-hypokinetic evolution of hypertrophic cardiomyopathy : prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients", J Am Coll Cardiol, 46, pp.1543~1550 (2005)
- Mitra A, "Significance of pulmonary hypertension in hypertrophic cardiomyopathy", Curr Probl Cardiol, 45, pp.100398~ (2020)
- Musumeci MB, "Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy", Int J Cardiol, 248, pp.326~332 (2017)
- Ong KC, "Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy", Eur Heart J Cardiovasc Imaging, 17, pp.604~610 (2016)
- Harris KM, "Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy", Circulation, 114, pp.216~225 (2006)
- Rowin EJ, "Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction", J Am Coll Cardiol, 75, pp.3033~3043 (2020)
- Marstrand P, "Hypertrophic cardiomyopathy with left ventricular systolic dysfunction : insights from the SHaRe Registry", Circulation, 141, pp.1371~1383 (2020)
- Nagueh SF, "American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy : Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography", J Am Soc Echocardiogr, 24, pp.473~498 (2011)
- Lang RM, "Recommendations for cardiac chamber quantification by echocardiography in adults : an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging", J Am Soc Echocardiogr, 28, pp.1~39 (2015)[DOI]
- Nagueh SF, "Recommendations for the evaluation of left ventricular diastolic function by echocardiography : an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging", J Am Soc Echocardiogr, 29, pp.277~314 (2016)
- Zoghbi WA, "Recommendations for noninvasive evaluation of native valvular regurgitation : a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance", J Am Soc Echocardiogr, 30, pp.303~371 (2017)
- Olivotto I, "Patterns of disease progression in hypertrophic cardiomyopathy : an individualized approach to clinical staging", Circ Heart Fail, 5, pp.535~546 (2012)
- Olivotto I, "The many faces of hypertrophic cardiomyopathy : from developmental biology to clinical practice", J Cardiovasc Transl Res, 2, pp.349~367 (2009)
- Eriksson MJ, "Long-term outcome in patients with apical hypertrophic cardiomyopathy", J Am Coll Cardiol, 39, pp.638~645 (2002)
- Losi MA, "Prognostic significance of left atrial volume dilatation in patients with hypertrophic cardiomyopathy", J Am Soc Echocardiogr, 22, pp.76~81 (2009)
- Covella M, "Mechanism of progressive heart failure and significance of pulmonary hypertension in obstructive hypertrophic cardiomyopathy", Circ Heart Fail, 10, pp.e003689~ (2017)
- Losi MA, "Heterogeneity of left ventricular filling dynamics in hypertrophic cardiomyopathy", Am J Cardiol, 73, pp.987~990 (1994)
- Thaman R, "Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy", J Am Coll Cardiol, 44, pp.398~405 (2004)
- Melacini P, "Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy", Eur Heart J, 31, pp.2111~2123 (2010)
- Hiemstra YL, "Development of and progression of overt heart failure in nonobstructive hypertrophic cardiomyopathy", Am J Cardiol, 122, pp.656~662 (2018)
- Rowin EJ, "Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy : under-recognized subset of candidates for heart transplant", Circ Heart Fail, 7, pp.967~975 (2014)
- Brinkley DM, "Avoiding burnout from hypertrophic cardiomyopathy", J Am Coll Cardiol, 75, pp.3044~3047 (2020)